, a major carrier of oxidized phospholipids (OxPL), is associated with an increased
Lipoprotein(a) (Lp [a] ) is a major carrier of oxidized phospholipids (OxPL) (4, 5) and has been established as a causal risk factor for AS in several genetic and population studies (6) (7) (8) . Lp(a) is unaffected by statin therapy, but levels can now be reduced with novel compounds (9) , making Lp(a) a potential therapeutic target in AS. The risk factors associated with incident AS may differ from those associated with disease progression, due to pathophysiological differences in the initiation and propagation phases of the disease (10) . Before Lp(a) or its associated OxPL can be considered viable targets for therapeutic intervention in AS, prospective longitudinal studies are required to establish whether Lp(a) and OxPL are associated with disease progression-in addition to mechanistic work investigating the cellular mechanisms linking Lp(a) and OxPL with valvular calcification.
In a prior study investigating patients with mild to moderate AS, elevated Lp(a) and OxPL on apolipoprotein B-100 (apoB) were associated with higher rates of disease progression determined by echocardiography, as well as an increased need for AVR (11) . However, this finding has not been validated in the elderly patients encountered in routine clinical practice nor in patients with more advanced aortic stenosis. Moreover, the relationship of Lp(a) and OxPL to sensitive measures of aortic valve calcification such as computed tomography (CT) calcium scoring or 18 F-sodium fluoride (NaF) positron emission tomography (PET) (a marker of calcification activity) has not been evaluated.
In this study, we analyzed a clinically representative cohort of patients with AS and compared baseline Lp(a) and OxPL-apoB levels to calcification activity in the aortic valve using 18 F-NaF PET; to future AS progression, as assessed both by echocardiography and CT calcium scoring; and to future clinical events. In parallel, we performed mechanistic in vitro experiments to investigate the effects of Lp(a) and OxPL on valvular interstitial cell (VIC) calcification and whether these effects may be counteracted.
METHODS STUDY POPULATIONS.
Patients investigated in this study were drawn from across 2 multimodality imaging studies that prospectively collected data with respect to AS progression and adverse clinical events:
the Ring of Fire study (12) In the Ring of Fire study, patients age >50 years and matched control subjects were recruited from the outpatient department of the Edinburgh Heart
Centre. PET, CT calcium scoring, and echocardiography were performed to assess disease activity and progression in a total of 81 patients. and OxPL-apoB measurements and available echocardiographic progression data were included: 65 of 155 (41.9%) patients. These patients had similar baseline characteristics compared with the subjects in whom baseline Lp(a) and OxPL measurements were not available (Online Table 1 ).
LP(A), OxPL AND AUTOTAXIN MEASUREMENTS.
Plasma Lp(a) and OxPL-apoB were measured in all patients in both cohorts using chemiluminescent immunoassays, as previously described (11) . Autotaxin (ATX) associated with Lp(a) and apoB was also measured (5).
BASELINE CALCIFICATION ACTIVITY WITH 18 F-NaF PET.
18 F-NaF PET provides a measure of valvular calcification activity in aortic stenosis, binding preferentially to developing tissue microcalcification and predicting AS progression (12, (14) (15) (16) (17) . In this study, aortic valve calcification activity was assessed at baseline in the Ring of Fire cohort using 18 F-NaF PET/CT on a hybrid scanner (Biograph mCT, Siemens
Medical Systems, Erlangen, Germany) 60 min after administration of 125 MBq of 18 F-NaF.
PET data were reconstructed with the use of the Siemens Ultra-HD reconstruction algorithm. Corrections were applied for attenuation, dead time, scatter and random coincidences. Image analysis was F-NaF PET uptake at baseline (left), which predicted progression to macrocalcification on CT after 2 years (right) (16) . Patients in the top Lp(a) and OxPL-apoB tertiles also demonstrated faster progression in aortic valve CT calcium score (D and E), and faster hemodynamic progression, expressed as the annualized change in peak aortic jet velocity (DV max ) (F and G). Abbreviations as in Figure 1 .
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was not included in the multiple regression analysis (Online Table 2 ). Kaplan-Meier curves of time-toevent data were compared with the use of the logrank test. Cox proportional hazards models were used to calculate hazard ratios by Lp(a) and OxPLapoB tertiles. Unpaired Student's t-tests were used to define differences between experimental conditions. Statistical analyses were performed using the SPSS statistics software version 24 (IBM, Armonk, New York). A p value <0.05 was considered statistically significant.
RESULTS

STUDY COHORT AND BASELINE CHARACTERISTICS.
After combining available data from the Ring of Fire cohort and the SALTIRE trial, a total of 145 elderly patients had samples available for Lp(a) and OxPLapoB measurements (Figures 2A and 2B) . In both studies, disease severity assessed by echocardiography was comparable (Online Table 3 ). The average age was 70.3 AE 9.9 years, and patients had a high prevalence of comorbidity. Baseline characteristics for the combined cohort are listed in Table 1 Table 2 , Online Table 5 ).
FASTER PROGRESSION OF CT CALCIUM SCORES IN PATIENTS WITH ELEVATED LP(A) AND OxPL-apoB.
Whether this increased calcification activity translated into faster progression of aortic valve calcium burden was subsequently assessed using repeat CT Zheng et al. Zheng et al. Table 5 ). Figures 1C and D) . Figures 5G and 5H ).
DISCUSSION
In this multimodality imaging study, we present the novel finding that increased Lp(a) and OxPL-apoB levels in elderly patients with advanced AS are associated with increased valvular calcification activity using 18 F-NaF PET and confirmed faster rates of disease progression using both CT calcium scoring and echocardiography (Central Illustration). This translated into an increased incidence of AVR and death.
In vitro studies demonstrated that these observations 
